HTG Molecular Diagnostics Inc. [HTGM] fell -89.11% so far this year. What now?


HTG Molecular Diagnostics Inc. [NASDAQ: HTGM] price surged by 5.36 percent to reach at $0.03. The company report on May 17, 2022 that HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

A sum of 4206154 shares traded at recent session while its average daily volume was at 643.15K shares. HTG Molecular Diagnostics Inc. shares reached a high of $0.648 and dropped to a low of $0.5351 until finishing in the latest session at $0.59.

The one-year HTGM stock forecast points to a potential upside of 93.79. The average equity rating for HTGM stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on HTG Molecular Diagnostics Inc. [HTGM]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HTGM shares is $9.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HTGM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for HTG Molecular Diagnostics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 11, 2020. The new note on the price target was released on March 26, 2020, representing the official price target for HTG Molecular Diagnostics Inc. stock. Previously, the target price had yet another raise from $4.50 to $6, while Rodman & Renshaw kept a Buy rating on HTGM stock.

The Average True Range (ATR) for HTG Molecular Diagnostics Inc. is set at 0.10, with the Price to Sales ratio for HTGM stock in the period of the last 12 months amounting to 0.63. The Price to Book ratio for the last quarter was 0.42, with the Price to Cash per share for the same quarter was set at 2.30.

HTGM Stock Performance Analysis:

HTG Molecular Diagnostics Inc. [HTGM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.75. With this latest performance, HTGM shares dropped by -38.92% in over the last four-week period, additionally sinking by -85.78% over the last 6 months – not to mention a drop of -84.47% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTGM stock in for the last two-week period is set at 29.65, with the RSI for the last a single of trading hit 31.40, and the three-weeks RSI is set at 29.67 for HTG Molecular Diagnostics Inc. [HTGM]. The present Moving Average for the last 50 days of trading for this stock 1.1145, while it was recorded at 0.5917 for the last single week of trading, and 3.6824 for the last 200 days.

Insight into HTG Molecular Diagnostics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and HTG Molecular Diagnostics Inc. [HTGM] shares currently have an operating margin of -205.48 and a Gross Margin at +54.02. HTG Molecular Diagnostics Inc.’s Net Margin is presently recorded at -192.49.

Return on Equity for this stock declined to -137.80, with Return on Assets sitting at -52.23.

HTG Molecular Diagnostics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 3.00.

HTG Molecular Diagnostics Inc. [HTGM] Insider Position Details

There are presently around $2 million, or 26.90% of HTGM stock, in the hands of institutional investors. The top three institutional holders of HTGM stocks are: ARMISTICE CAPITAL, LLC with ownership of 834,054, which is approximately New of the company’s market cap and around 0.30% of the total institutional ownership; COWEN PRIME SERVICES LLC, holding 570,333 shares of the stock with an approximate value of $0.32 million in HTGM stocks shares; and SAMJO CAPITAL LLC, currently with $0.23 million in HTGM stock with ownership of nearly -31.362% of the company’s market capitalization.

Positions in HTG Molecular Diagnostics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 13 institutional holders increased their position in HTG Molecular Diagnostics Inc. [NASDAQ:HTGM] by around 927,783 shares. Additionally, 8 investors decreased positions by around 1,262,810 shares, while 9 investors held positions by with 676,555 shares. The mentioned changes placed institutional holdings at 2,867,148 shares, according to the latest SEC report filing. HTGM stock had 6 new institutional investments in for a total of 866,165 shares, while 5 institutional investors sold positions of 767,785 shares during the same period.